PharmaWeek
Wed., Nov. 5, 2008 |  PharmaWeek.com | Archives | Advertising | Your Account | CHI Conferences |  Subscribe |

Industry Trends

U.S. Generic Drug Market Outlook to 2012
By Mark P. Mathieu

Since drugs with $50 billion on 2007 U.S. sales are scheduled to lose patent/exclusivity protection in 2008 – 2010, the three-year period presents formidable obstacles for the pharmaceutical industry. Marketing exclusivity … Read more

Sales Contacts
For advertising information contact: 

Tom Loughran
Regional Sales Manager, Advertising Sales -Midwest, South Eastern US, Europe
781-972-5482

Contact the Editor
Alissa PohPharmaWeek welcomes your feedback. Please contact Alissa Poh for editorial inquiries.

Link to Us! 
You are welcome to link to articles on our website. Contact Catherine Varmazis for details.

e-Prints & Reprints 
To post a full article from PharmaWeek or Bio-IT World on your website (not just a link), or for paper reprints, please contact:
Ashley Zander
The YGS Group
717-399-1900 ext.125

Dear Colleague,
Welcome to this week's eNewsletter covering breaking R&D news, business insights, and a feature on Tranzyme Pharma's work with the "hunger hormone" ghrelin as a potential way of treating GI disorders.
 

 
 
FEATURE  
 

Of Ghrelin and the Gut: Tranzyme Pharma
By Alissa Poh

When the Human Genome Project first took off, the genomics space teemed with life science entrepreneurs, all raring to create startups. It was no different for those who started Tranzyme Pharma.

“Our original idea was to create cell lines that behaved more like human cells, for drug discovery,” says Vipin Garg, Tranzyme’s scientist-turned-CEO. “Whereas most genes are delivered in cis, we had the technology to do so in trans, which explains our company’s name.” Many post-genomics companies died a slow but sure death, however, when the model on which they were based failed to produce exciting blockbuster drugs, as promised. Tranzyme’s story, on the other hand, is one of embracing evolution – a key ingredient when it comes to keeping a small biotech on its feet. More

 
 
BREAKING R&D NEWS
 

The Safety Gap – Chinese Biogenerics
New York Times [Oct 31] Just how safe are the Chinese factories that are poised to become a key global supplier of generic drugs in the not too distant future? More

Speedy FDA Approval Puts Stehlin Anticancer Drug in Clinical Trials
Houston Business Journal [Oct 31] A promising anticancer drug developed by the Christus Stehlin Foundation for Cancer Research in Houston is being tested on patients after quickly receiving approval from the FDA for Phase I clinical trials. The drug, CZ48, is derived from a Chinese tree, Camptotheca, whose anticancer potential was discovered in the 1960s. More

Gleevec Holds Potential As First Drug To Successfully Treat Neurofibromatosis
ScienceDaily [Oct 31] Researchers at the Indiana University School of Medicine report that the anti-cancer drug Gleevec holds out promise to become the first effective treatment for neurofibromatosis, a genetic disease that has resisted treatments until now. IU researchers have begun a Phase 2 clinical test of Gleevec, treating patients with plexiform neurofibromas. More

Blocking Enzyme May Help Childhood Leukemia
Yahoo! News [Nov 3] Researchers at Children’s Hospital Boston have found that blocking the enzyme Dot1 may prevent genetic switches causing ALL from being flipped on, potentially paving the way for a new class of anticancer drugs. More

Tests Could Predict Benefit From Cancer Drugs
Yahoo! News [Oct 29] Tests based on genes or other molecular markers have the potential to predict the usefulness of a particular cancer therapy, for patients battling colon, lung and pancreatic tumors. More

 
 
BUSINESS INSIGHTS 
 

Pfizer CEO Kindler Has His Work Cut Out for Him
BusinessWeek [Oct 31] Investors want a fresh perspective for post-Lipitor Pfizer, but they're not yet convinced outsider Kindler is the one to bring it. More

Four New Pharmaceutical CEOs Speak Out
BusinessWeek [Oct 30] The CEOs of Pfizer, Roche, Eli Lilly, and Bristol-Myers Squibb address topics from dealmaking to the pharmaceutical industry's image problems. More

Osiris Leaps on $1.38 Billion Genzyme Stem-Cell Deal
MarketWatch [Nov 4] Osiris and Genzyme announced today that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult stem cell treatments that hold significant potential to treat a wide range of diseases. More

Taking Statins To The Next Level
Forbes [Oct 29] A forthcoming study funded by Crestor maker AstraZeneca suggests that statins can work against heart disease in some people with low cholesterol levels. If so, another 12 million people should be taking the drugs. More

Job Cuts Loom as Glaxo Revamps U.S. Operations
Reuters [Nov 4] GSK staff in the U.S. are braced for further job cuts as Chief Executive Andrew Witty prepares to announce a reorganisation of pharmaceutical operations in the group's biggest market. More

Genentech Seeks Avastin Approval in Brain Cancer
Forbes [Nov 3] Genentech has asked the FDA to approve the extended use of Avastin (beyond lung, breast and colorectal cancers) as a secondary treatment for glioblastoma. More

More R&D: Not Boosting Big Pharma
BusinessWeek [Oct 29] Despite stepped-up levels of research spending, drug outfits are launching fewer new products, says S&P. More

 
 
LAST WEEK'S TOP STORY
 

The Research Triangle Park: 50 Years of Innovation
PharmaWeek [Oct 29] There’ll be much feasting and merrymaking next January – big administration changes aside, that is – when North Carolina’s Research Triangle Park celebrates its golden anniversary. And its leaders will also have opportunities galore to reflect on various trials and triumphs that have marked the last several decades, since RTP’s inception in 1959. More

For More Recent Articles >>

 

LIFE SCIENCE JOBS

Memorial Sloan-Kettering Cancer Center - Linux Systems Administrator
MSKCC Bioinformatics Core in Manhattan seeks Linux System
Administrator. Install, configure, update, monitor and troubleshoot HPC cluster, email and web servers. Master's degree and 5 years experience with HPC, network security, Postfix, Apache, Tomcat, Grid Engine, Solaris. Email bicjobs@cbio.mskcc.org or www.mskcc.org #015429. EOE/AA

MedImmune INC. - Associate Director, Development Information Systems
Associate Director, Development Information Systems (Gaithersburg, MD): Responsible for IS strategy for the global Development organization, implementation and oversight of the ongoing projects and support of existing systems.  If you are interested in this position, apply online at www.medimmune.appone.com and search for Req 01124.
 

More Life Science Jobs ~ Add a Job Listing

 

FEATURED EVENTS

Super Computing ~ November 15-21, Austin, TX 

Fifth Annual Molecular Imaging Week ~November 17-19, 2008, La Jolla, CA

The Next Tool for Healthcare Innovation~Nov 20, 2008 2pm EST A Complimentary Frost & Sullivan eBroadcast

The 4th Annual World Healthcare Innovation and Technology Congress - December 8 – 10, 2008 | Washington, DC

The Association for Laboratory Automation (ALA) presents LabAutomation2009, January 24-28, in Palm Springs, CA. 

TEPR+ 2009 - Feb 1-5, 2009 | Palm Springs, CA

The World Health Care Congress 2nd Annual Leadership Summit on Consumer Connectivity & Web Empowerment | February 23 – 24, 2009-Carlsbad, CA

7th Annual Bio-IT World Conference - April 2009

Storage for Science Seminar Series-See Schedule Here

Barnett Educational Services

Cambridge Healthtech Events

To have your event featured here, contact Lynn Cloonan for more information.

 Email to a Friend 

FROM THE EDITOR

Alissa Poh 

Another story from North Carolina's RTP this week - and then there'll be a break. It should be interesting to see what happens with Tranzyme over the next several months, on the economic development side of things. For those of you who may have skipped last week's issue, PharmaWeek will cover more economic development issues over time, either via a regular section or updates in a special edition every so often. As always, contact me at apoh@healthtech.com if you have suggestions and feedback. 

EXCLUSIVE WEBCAST

Life Science Webcasts from Bio-IT World and Cambridge Healthtech Media Group

Life Science Webcasts

Bio-IT World Expo
Video Highlights

Drug Discovery, Development and Commercialization: Evolving Challenges and Opportunities
Joshua Boger, PhD, president and CEO, Vertex Pharmaceuticals Inc., delivers his keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 2008.
View the Webcast Now.

Personalized Genetics: Advancements and Driving Change
Linda Avey, co-founder of 23andMe, delivers her keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.
View the Webcast Now.

The Future of Personal Genomics
A distinguished panel of personal genomics experts discuss the future of personal genomics at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.  They include Dietrich Stephan (co-founder, Navigenics); George Church (Harvard Medical School);
Jeff Drazen (editor-in-chief, New England Journal Medicine); Fred Ledley (Bentley College); John Halamka (CIO, Harvard Medical School); and Linda Avey (23andMe). Bio-IT World Editor-in-Chief Kevin Davies moderates the discussion.
View the Webcast Now

Bio-IT World's 2009
Best Pract
ices Awards

Entry forms are now available for Bio-IT World’s 2009 Best Practices Awards program. This has long been one of our most successful programs. Last year, there were 56 entries and we awarded 15 prizes at a gala dinner held during the Bio-IT World Conference & Expo in the spring. This year we are hoping to expand those numbers. 
The program is intended to spotlight companies whose use of innovative technologies is making a positive difference in biomedical R&D and drug discovery and development.
Bio-IT World is also making available a free compendium of Best Practice entries from 2008 to help ensure the lessons learned are widely spread. The compendium can be downloaded here.

Meanwhile, get started on this year’s entries. There are nine categories, shown below. The deadline is mid-January 2009. Full details of the entry process and the entry form are available by clicking here.

2009 Best Practices Categories:
*Basic Research & Biological Research
*Drug Discovery & Development
*Clinical Trials & Research
*Translational Medicine
*Personalized Medicine
*IT & Informatics
*Knowledge Management
*Health-IT
*Manufacturing & Bioprocessing

All of the entries will be reviewed and ranked by a panel of experts assembled by Bio-IT World editors. Winners will be announced at a dinner ceremony held in Boston in April 2009 in conjunction with the Bio-IT World Conference & Expo. If you have questions, write to john_russell@bio-itworld.com 


Insight Pharma Reports

Immunotherapies and Vaccines for Cancer and Infectious Diseases

Reviews immunotherapies and vaccines currently available and in development for cancer and infectious diseases; the market opportunity; R&D challenges; business considerations. More Information

Featured Content

Managed Innovation, 
Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
sponsored by SAS
 

Discovery organizations are identifying a lot of promising compounds, but clinical research processes haven't kept pace with timely testing of all those potential therapies. This white paper describes how SAS Drug Development supports true innovation across the clinical trial process.
In this white paper you will learn how to:
~Assemble data to foster better collaboration
~Get up-to-date information during clinical trials
~Make informed decisions earlier in the trial process
Download now
 

Addressing Life Sciences Constantly Growing Data Challenges Research Environments sponsored by BlueArc

The continued explosion of raw experimental data, the increased use of video, the growingadoption of new data retention practices, and the move to high throughput computational workflows are all placing new demands on the way life sciences organizations store and manage their data.
Download this white paper to learn about:
• Factors driving the data explosion in the life sciences
• New data management issues that must be addressed
• HPC trends that are placing new demands on storage
• Storage solution attributes that address performance, manageability, and energy efficiency. Download now

“Storage for Science – Methods for Managing Large and Rapidly Growing Data Stores in Life Science Research Environments” sponsored by Isilon

Large and rapidly growing stores of file-based and other data are a hallmark of life science research and bioinformatics. Determining how best to manage those data stores has become a significant challenge for Researchers and IT Pros alike.  This paper is intended to:  Provide guidance on the many storage  requirements common to Life Science research;  Explain the evolution of modern storage architectures; Summarize the major data storage architectures currently in use.  Additionally, it will present the Isilon IQ clustered storage product as a strong and flexible solution to those needs. Download now
 

Microsoft’s BioIT Alliance

Bio-IT World published a special supplement with support from Microsoft and their Alliance members. The supplement provides insight into the activities of the Alliance and their partners. Click here to access the Supplement PDF.

To have your white paper featured here, contact Lynn Cloonan for more information.


Cambridge
                                Healthtech InstitutePublished by Cambridge Healthtech Institute (CHI). Copyright © 2008, all rights reserved. No material may be reproduced electronically or in print without written permission from CHI, 250 First Ave., Needham, MA 02494-2814. For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA; 17601 717-399-1900 ext.125, or email: Ashley.Zander@theYGSgroup.com